spacer
home > ebr > spring 2002 > 2nd annual bia european ceo & investor conference - 27th-28th november 2001, london
PUBLICATIONS
European Biopharmaceutical Review

2nd Annual BIA European CEO & Investor Conference - 27th-28th November 2001, London

The theme of the BIA's successful 2nd Annual CEO & Investor Conference, held in London towards the end of last year was 'From Promise to Products'. This was a timely choice given the re-focus of investor sentiment which underscored the market conditions for life science investing throughout 2001 and has continued in the first quarter of 2002. The name of the game is developing products to deliver long-term and sustainable value (nothing new there, of course) and this was the underlying proposition behind all of the elements of this two-day conference. Run by the BIA in partnership with Technology Vision Group (TVG), the aim of the CEO & Investor Conference was to provide a platform for both public and private European companies and their investors to present to, and engage with, each other on the product delivery question. This assumed various structured forms including moderated CEO roundtable discussions, which were also co-ordinated to illustrate different case scenarios for acceleration towards products. In addition, there were themed investor panels that focused on innovation in both science and partnering plus the leveraging of intellectual property assets to raise finance. Beyond the parallel CEO and investor panels, the third track featured a series of European company presentations from a range of public and private European companies across multiple technology platforms and therapeutic areas - all with one element in common: the drive towards products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark and Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SEKISUI XenoTech Receives New US Patent for a Method to Evaluate Xenobiotics as Immune-Modulators of Drug Transport and Metabolism in Hepatocytes

Kansas City, KS- SEKISUI XenoTech has been awarded US patent # 10,648,968 “In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes.”
More info >>

White Papers

Environmental Factors in Data Centres

Dycem

In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiña of Secure Techincal Rooms.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement